This is stated in a message on the regulator's website.

It is noted that the drug is allowed to be used only for the prevention of immunocompromised people who have a bad reaction to vaccines.

Evusheld is a combination of two monoclonal antibodies.

Earlier, the president of the American pharmaceutical company Moderna Stephen Hoag said that there is a risk of reducing the effectiveness of vaccines due to the emergence of a new strain of coronavirus "omicron".